Cardiovascular Metabolic Treatment Devices and Methods - US20260108742A1
Summary
USPTO published patent application US20260108742A1 on April 23, 2026, filed October 13, 2025, covering devices and methods for treating cardiovascular and metabolic disease through activation and deactivation of vascular baroreceptors. Inventors Ryan Kendall Pierce and Benjamin Kahn Cline disclose therapeutic applications including hypertension, hypotension, metabolic disorders, cardiovascular disease, heart failure, cardiac arrhythmia, renal disease, respiratory disease, diabetes, and insulin resistance. The application covers CPC classifications spanning A61N (electrical therapy), A61B (diagnosis/surgery), A61M (medical devices), and A61F (implants/prostheses).
“Devices and methods described herein may, among other uses, favorably cause the activation and/or deactivation of vascular baroreceptors in order to achieve a desired impact on a physiological condition, such as baroreflex-regulated conditions, hypertension, hypotension, nervous system disorders, metabolic disorders, cardiovascular disease, heart failure, cardiac arrhythmia, renal disease, respiratory disease, diabetes, and insulin resistance.”
About this source
USPTO classification A61M covers devices that introduce or withdraw fluids from the body: infusion pumps, catheters, syringes, inhalers, wound drainage, dialysis equipment, and fluid-handling microfluidics. Every newly published application in A61M lands in this feed, around 205 a month. Applications publish 18 months after filing. Watch this if you compete in infusion therapy or drug delivery, file freedom-to-operate analyses for medical device startups, scout acquisition targets in cardiovascular or respiratory devices, or track hospital R&D arms that are quietly patenting clinical innovations.
What changed
USPTO published patent application US20260108742A1 disclosing medical devices and methods for treating cardiovascular and metabolic conditions through vascular baroreceptor manipulation. The application covers therapeutic approaches to hypertension, hypotension, nervous system disorders, metabolic disorders, cardiovascular disease, heart failure, cardiac arrhythmia, renal disease, respiratory disease, diabetes, and insulin resistance. The disclosed devices include those performing or assisting with blood pressure assessment, impact measurement, and protection of surrounding anatomy.
Medical device manufacturers developing cardiovascular, electrophysiology, or metabolic treatment devices should review the published claims for potential licensing considerations or freedom-to-operate analysis. The baroreceptor activation/deactivation methodology disclosed may overlap with existing or planned product development programs in the vascular intervention and neuromodulation spaces.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
DEVICES AND METHODS FOR TREATING CARDIOVASCULAR AND METABOLIC DISEASE
Application US20260108742A1 Kind: A1 Apr 23, 2026
Inventors
Ryan Kendall Pierce, Benjamin Kahn Cline
Abstract
Devices and methods described herein may, among other uses, favorably cause the activation and/or deactivation of vascular baroreceptors in order to achieve a desired impact on a physiological condition, such as baroreflex-regulated conditions, hypertension, hypotension, nervous system disorders, metabolic disorders, cardiovascular disease, heart failure, cardiac arrhythmia, renal disease, respiratory disease, diabetes, and insulin resistance. The devices and methods may be used in concert with each other and/or other treatments, medications, interventions, or behavioral regimens. They may also be used in concert with devices and methods that perform or assist with assessing or measuring a mammal's blood pressure, assessing, measuring, or predicting the impact of the described methods and devices on the patient's condition (including blood pressure), and/or protecting the surrounding anatomy from adverse effects.
CPC Classifications
A61N 1/36564 A61B 5/0215 A61B 17/1204 A61B 17/12109 A61B 17/12136 A61B 17/320725 A61B 18/1492 A61B 18/1815 A61F 2/82 A61F 2/885 A61F 2/91 A61F 2/92 A61M 25/10 A61B 2017/22067 A61B 17/221 A61B 2018/00011 A61B 2018/00214 A61B 2018/0022 A61B 2018/00267 A61B 2018/00345 A61B 2018/00404 A61B 2018/00791 A61B 2018/00994 A61B 2018/0212 A61F 2002/068 A61F 2002/825 A61F 2/915 A61F 2002/91533 A61F 2250/0031 A61M 2025/0681 A61M 25/1011 A61M 2025/1015 A61M 2025/1052 A61N 2007/0043
Filing Date
2025-10-13
Application No.
19356394
Related changes
Get daily alerts for USPTO Patent Applications - Medical Devices (A61M)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Medical Devices (A61M) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.